Synthesis and anticancer activity of some pyrido[2,3-]pyrimidine derivatives as apoptosis inducers and cyclin-dependent kinase inhibitors.

Clicks: 463
ID: 61344
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #2 of 41 articles by views in Future medicinal chemistry

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Due to emergence of resistance to available anticancer agents, there is a need to search for new cytotoxic agents. Pyrido[2,3-]pyrimidines (-) and their tricyclic derivatives () were prepared and screened for their cytotoxicity against breast MCF-7, prostate PC-3 and lung A-549 cancer cell lines as well as normal fibroblasts WI-38. The most active compounds were and compared with doxorubicin. Moreover, compounds and induced apoptosis in PC-3 and MCF-7, respectively via activation of CASP3 (in PC-3 only), Bax, p53 and down regulation of Bcl2 in addition to CDK4/6 inhibition. Pyrido[2,3-]pyrimidine represents an important core for discovery of new potent cytotoxic agents acting on the cell cycle via apoptosis induction through either intrinsic or extrinsic pathways.
Reference Key
abbas2019synthesisfuture Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Abbas, Safinaz E-S;George, Riham F;Samir, Eman M;Aref, Mostafa Ma;Abdel-Aziz, Hatem A;
Journal Future medicinal chemistry
Year 2019
DOI
10.4155/fmc-2019-0050
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.